Uncategorized
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd. announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of AZR-MD-001.